FAK activation upon BCR engagement had been already demonstrated on primary CLL cells by Lòpez-Guerra et al., who also showed how this process can be inhibited by the multi-kinase inhibitor sorafenib (10 μM) (29). This evidence concerns the gene PTK2 and B-cell chronic lymphocytic leukemia.